Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Deciphera Pharmaceuticals (NASDAQ: DCPH) announced participation in key investor conferences. Management will engage in fireside chats at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 2:50 PM ET in New York, and at the Barclays Global Healthcare Conference on March 15, 2023, at 5:00 PM ET in Miami Beach. Both sessions will be webcast live on the company's website, with replays available for 90 days. Deciphera focuses on innovative cancer treatments, notably the approved QINLOCK® for fourth-line GIST, available in major markets including the US, UK, and Australia. For more information, visit www.deciphera.com.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:

• Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 2:50 PM ET in New York, NY
• Barclays Global Healthcare Conference on Wednesday, March 15, 2023 at 5:00 PM ET in Miami Beach, FL

A live webcast of both events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of both webcasts will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Israel, Macau, New Zealand, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005070/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902

Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

When is Deciphera Pharmaceuticals participating in the Cowen 43rd Annual Health Care Conference?

Deciphera Pharmaceuticals will participate in the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 2:50 PM ET in New York.

What is the date for Deciphera's participation in the Barclays Global Healthcare Conference?

Deciphera Pharmaceuticals will be at the Barclays Global Healthcare Conference on March 15, 2023, at 5:00 PM ET in Miami Beach.

Where can I watch the live webcasts of Deciphera Pharmaceuticals' investor conferences?

Live webcasts of Deciphera Pharmaceuticals' investor conferences will be available on the ‘Events and Presentations’ page in the ‘Investors’ section of their website.

What is QINLOCK and where is it approved?

QINLOCK is Deciphera's switch-control inhibitor for the treatment of fourth-line GIST, approved in the US, UK, Australia, and other major markets.

How long will the webcasts of Deciphera's events be available for replay?

The replays of Deciphera Pharmaceuticals' webcasts will be archived for 90 days following the presentations.